What is the importance of difference in LCM strategy in drug development? - Learnings from Keytruda and Opdivo

Kota Kodama; Arisa Djurian; Yeongjoo Lim

doi:10.1016/j.drudis.2022.103390

What is the importance of difference in LCM strategy in drug development? - Learnings from Keytruda and Opdivo

Drug Discov Today. 2022 Dec;27(12):103390. doi: 10.1016/j.drudis.2022.103390. Epub 2022 Oct 9.

Authors

Kota Kodama¹, Arisa Djurian², Yeongjoo Lim³

Affiliations

¹ Graduate School of Technology Management, Ritsumeikan University, Osaka 567-8570, Japan; Center for Research and Education on Drug Discovery, The Graduate School of Pharmaceutical Sciences in Hokkaido University, Sapporo 060-0812, Japan. Electronic address: kkodama@fc.ritsumei.ac.jp.
² Graduate School of Technology Management, Ritsumeikan University, Osaka 567-8570, Japan.
³ Faculty of Business Administration, Ritsumeikan University, Osaka 567-8570, Japan.

PMID: 36223857
DOI: 10.1016/j.drudis.2022.103390

Abstract

Immune checkpoint inhibitors have changed how cancer is treated. As of February 2022, six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the differences in commercial success between Keytruda and Opdivo is reviewed by analyzing inter-organizational deals since their launch in 2014. Both showed a correlation between the cumulative number of indications and product sales trends, the latter crossing from 2017 to 2018. Differences in sales were due to different approaches to life cycle management by inter-organizational deals and drug development strategies, the key to commercial success.

Keywords: Combination therapy; Inter-organizational transaction; Keytruda; Opdivo; iPD-(L)1 inhibitors.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Drug Development
Immune Checkpoint Inhibitors*
Nivolumab*

Substances

Nivolumab
pembrolizumab
Immune Checkpoint Inhibitors
Antibodies, Monoclonal, Humanized